Please assess the completion status of the following clinical trial:

Trial Title: SNAP 25 Gene Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients will be male or female outpatients who are at least 6 years of age (there is no upper age limit)~2. Patients must meet DSM-IV criteria for ADHD~3. Patients and parents/guardians must have a degree of understanding sufficient to be able to communicate suitably with the investigator and study coordinator~4. Patients must have tolerated the drug at therapeutic doses, but have shown a true lack of improvement in symptoms~5. Must have shown clinically significant superiority in improvement in ADHD symptoms on amphetamine relative to MPH.~Exclusion Criteria:~1. Must not have a true allergy to methylphenidate or amphetamines~2. Must not have a history of serious adverse reactions to methylphenidate

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).